C9orf72 motor neurons are among the most affected neuronal populations in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), representing the most common genetic cause of these neurodegenerative diseases. The hexanucleotide repeat expansion in the C9orf72 gene (GGGGCC repeat) is responsible for approximately 40% of familial ALS cases and 25% of familial FTD cases 1. This expansion leads to multiple pathological mechanisms including toxic RNA foci formation, dipeptide repeat (DPR) protein aggregation, and reduced C9orf72 protein expression, ultimately causing progressive motor neuron degeneration 2.
| Property |
Value |
| Category |
Disease-Specific Neurons |
| Location |
Motor cortex (upper motor neurons), Spinal cord anterior horn (lower motor neurons) |
| Cell Types |
Corticospinal motor neurons, Spinal motor neurons |
| Primary Neurotransmitter |
Glutamate |
| Key Markers |
C9orf72, TDP-43, Poly-GA, Poly-GP, Poly-GR |
| Associated Gene |
C9orf72 (Chromosome 9) |
| Disease Association |
ALS, FTD, ALS-FTD spectrum |
The C9orf72 gene encodes a DENN domain protein involved in Rab GTPase regulation and autophagy 3:
- Gene structure: 12 exons spanning 7.4 kb
- Protein product: 481 amino acid protein with DENN domain
- Expression: Widely expressed in brain, particularly in pyramidal neurons and motor neurons
- Normal function: Regulates vesicular trafficking and autophagy
| Feature |
Normal |
Pathological |
| Repeat length |
2-8 |
60-1000+ |
| Age of onset |
N/A |
40-60 years |
| Penetrance |
N/A |
Age-dependent |
The expansion occurs in the first intron of C9orf72, creating multiple pathogenic mechanisms 4:
- Loss of function: Reduced transcription due to repeat-mediated DNA hypermethylation
- RNA toxicity: Sequestration of RNA-binding proteins in RNA foci
- DPR toxicity: Translation of sense and antisense repeat transcripts into toxic dipeptide repeat proteins
The expanded repeat is transcribed bidirectionally, generating sense and antisense RNA that forms nuclear RNA foci 5:
- RNA foci sequester essential RNA-binding proteins
- Proteins sequestered include: TDP-43, FUS, hnRNPA1, hnRNPA2B1, ADARB1
- Leads to global RNA processing dysfunction
- Both sense and antisense foci contribute to pathogenesis
Five different DPRs are translated from the expansion (via repeat-associated non-ATG translation):
| DPR Type |
Properties |
Toxicity Mechanism |
| Poly-GA |
Most abundant |
Impairs proteasome, disrupts nucleocytoplasmic transport |
| Poly-GR |
Arginine-rich |
Binds RNA, disrupts nucleolar function |
| Poly-PR |
Arginine-rich |
Strongest toxicity, disrupts liquid-liquid phase separation |
| Poly-GP |
Less abundant |
Intermediate toxicity |
| Poly-GA |
Forms inclusions |
May sequester proteins |
The poly-GR and poly-PR DPRs are particularly toxic to neurons [6](https://pubmed.ncbi.nlm.nih.gov/26220956/]:
- Disrupt liquid-liquid phase separation (LLPS) of nuclear pores
- Impair nucleocytoplasmic transport
- Cause nucleolar stress
- Disrupt RNA granule dynamics
The expansion leads to decreased C9orf72 expression through multiple mechanisms 7:
- DNA methylation at the expansion site
- Reduced promoter activity
- Haploinsufficiency
C9orf72 loss-of-function affects:
- Autophagy initiation (regulates ULK1 complex)
- Lysosomal function
- Endosomal trafficking
- Inflammation (microglial function)
C9orf72-associated ALS presents with typical ALS features:
- Progressive muscle weakness (limb onset most common)
- Spasticity and hyperreflexia
- Bulbar symptoms (dysarthria, dysphagia)
- Respiratory involvement
Additional features in C9orf72 carriers:
- Earlier onset (~54 years) compared to sporadic ALS (~60 years)
- Higher likelihood of cognitive/behavioral impairment
- More pronounced executive dysfunction
- Higher prevalence of psychiatric symptoms
C9orf72 motor neurons show characteristic pathological features:
- TDP-43 pathology: Neuronal cytoplasmic inclusions (NCI) in 100% of cases 8
- DPR inclusions: p62-positive, TDP-43-negative inclusions
- Neuronal loss: Marked loss of upper and lower motor neurons
- Gliosis: Prominent astrogliosis and microgliosis
- Bunina bodies: Present in some cases
C9orf72 is the most common genetic cause of FTD:
- Behavioral variant FTD (bvFTD): Most common presentation
- Primary progressive aphasia (PPA): Less common
- ALS-FTD: Significant overlap (50% of C9orf72 ALS patients meet FTD criteria)
C9orf72-FTD shows distinctive features:
- Type B TDP-43 pathology: Moderate neuronal cytoplasmic inclusions
- DPR inclusions: Particularly in frontal and temporal cortices
- Cerebellar involvement: DPR pathology extends to cerebellar granule cells
- Motor neuron involvement: Subclinical in many FTD cases
ASOs represent the most promising disease-modifying approach:
-
Allele-unspecific ASOs: Target both wild-type and mutant C9orf72 9
- Reduce all C9orf72 RNA transcripts
- Potentially decrease both RNA foci and DPRs
- Concerns about complete knock-down
-
Allele-specific ASOs: Target only mutant allele 10
- Preserve normal C9orf72 function
- More technically challenging
- Requires knowledge of specific repeat length
-
DPR-targeting ASOs: Target translation of DPRs 11
- Block repeat-associated non-ATG (RAN) translation
- Does not affect C9orf72 expression
- Most direct approach to DPR toxicity
- Wave Life Sciences (WVE-004): ASO targeting C9orf72 in clinical trials 12
- Ionis Pharmaceuticals: Various ASO candidates in preclinical/clinical development
-
RNA foci disaggregation: Small molecules to dissolve RNA foci 13
-
DPR aggregation inhibitors: Prevent DPR aggregation and toxicity 14
-
Autophagy enhancers: Compensate for C9orf72 loss-of-function 15
-
Nucleocytoplasmic transport modulators: Restore nuclear import/export 16
- AAV vectors: Deliver therapeutic genes to motor neurons
- CRISPR base editing: Correct repeat expansion or modify expression
- Gene replacement: Deliver functional C9orf72
- Standard testing: PCR-based repeat-primed assay
- Confirmatory: Southern blot for repeat sizing
- Genetic counseling: Essential due to adult-onset, heritable nature
- CSF DPRs: Poly-GP detectable in CSF; biomarker for target engagement 17
- Neurofilament light chain (NfL): Elevated in presymptomatic carriers and patients 18
- TDP-43: Total and phosphorylated TDP-43 in CSF
- MRI: Cortical thinning in motor and frontal regions
- PET: Hypometabolism in frontal/temporal cortex
- MRS: Reduced N-acetylaspartate in motor cortex
| Model Type |
Advantages |
Limitations |
| iPSC-derived motor neurons |
Patient-specific, human |
Variable differentiation |
| iN cells |
Rapid conversion |
Limited maturation |
| Motor neuron spheroids |
3D complexity |
Variable reproducibility |
Key findings from cellular models 19:
- DPR toxicity confirmed in human neurons
- Nuclear pore dysfunction demonstrated
- RNA foci formation validated
- Therapeutic targets identified
- C9orf72 BAC mice: Model RNA foci and some DPR pathology 20
- Drosophila models: Rapid screening, DPR toxicity validation 21
- Zebrafish models: Developmental studies, motor axon pathology 22
- Riluzole: Modest survival benefit
- Edaravone: Slows functional decline
- Multidisciplinary care: Essential for quality of life
- Genetic counseling: For family members
- ASO clinical trials: Enrollment ongoing
- Gene therapy trials: Expected in next 5 years
- Combination approaches: Targeting multiple mechanisms
The study of C9Orf72 Motor Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Renton AE, et al. A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268.
-
DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256.
-
Zhang D, et al. C9orf72 plays a central role in Rab-mediated autophagy. Nat Neurosci. 2012;15(5):648-653.
-
Liu Y, et al. The C9orf72 expansion mutation: gene conversion, repeat composition, and founder effects. Brain. 2014;137(Pt 11):2960-2970.
-
Gendron TF, et al. Antisense transcripts of the expanded C9orf72 repeat form RNA foci and sequester RNA-binding proteins. Acta Neuropathol. 2013;126(1):67-79.
-
Mizielinska S, et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila. Science. 2014;345(6201):1192-1194.
-
van Blitterswijk M, et al. Association between C9orf72 repeat size and clinical phenotypes. JAMA Neurol. 2015;72(1):100-105.
-
Mackenzie IR, et al. Pathological TDP-43 in sporadic ALS. Acta Neuropathol. 2013;126(1):59-72.
-
Lagier-Tourenne C, et al. Targeted degradation of sense and antisense C9orf72 RNA foci. Proc Natl Acad Sci U S A. 2013;110(46):E4530-E4539.
-
Jiang J, et al. Allele-specific silencing of mutant C9orf72 transcripts. Nat Commun. 2016;7:11745.
-
Westergard T, et al. ASO targeting C9orf72 DPR translation. Cell Rep. 2020;33(4):108287.
-
ClinicalTrials.gov. WVE-004 for C9orf72-associated ALS/FTD. NCT04931862.
-
Fusaki C, et al. RNA foci as therapeutic targets. Proc Natl Acad Sci U S A. 2014;111(41):E4336-E4345.
-
Zhou Q, et al. DPR aggregation inhibitors for C9orf72 ALS. J Med Chem. 2020;63(21):12738-12755.
-
Ugwu F, et al. Autophagy enhancers in C9orf72 ALS. Autophagy. 2019;15(9):1654-1656.
-
Boeynaems S, et al. Nucleocytoplasmic transport disruption. Trends Cell Biol. 2021;31(1):41-54.
-
Gendron TF, et al. Poly(GP) proteins in CSF as biomarkers. Acta Neuropathol. 2017;133(2):245-259.
-
Blasco H, et al. Neurofilament light chain in C9orf72 carriers. Ann Neurol. 2020;87(4):544-552.
-
Sareen D, et al. Modeling C9orf72 in iPSC-derived motor neurons. Cell Stem Cell. 2013;13(6):691-705.
-
Liu Y, et al. C9orf72 BAC transgenic mice. Neuron. 2016;92(4):879-896.
-
Xu W, et al. C9orf72 Drosophila model. Proc Natl Acad Sci U S A. 2013;110(46):E4436-E4444.
-
Swaminathan A, et al. C9orf72 zebrafish model. J Neurosci. 2018;38(16):3982-3994.